 mitoxantron intermediate-dos cytarabin effect toler regimen treatment refractori acut myeloid leukemia thirty-two patient refractori acut myeloid leukemia aml salvag therapi singl cours mitoxantron intraven IV bolu IV period hour cytarabin ara-c IV period hour day mec eighteen patient resist convent daunorubicin ara-c induct treatment patient month initi remiss patient bone marrow transplant bmt procedur overal patient complet remiss CR infect induct resist diseas age year factor predict respons rate median remiss durat week overal median surviv week sever myelosuppress patient fever infect patient nonhematolog toxic minim mec regimen signific antileukem activ accept toxic salvag aml benefit front-lin aml therapi